2025 ASCO Annual Meeting

The companies that generate the most seemingly favorable buzz during the annual ASCO conference aren’t necessarily the ones that are viewed most favorably by oncologists. 

Ipsos Healthcare will be on the ground at ASCO again this year to conduct competitive intelligence which will then be synthesized with the results of a robust quantitative survey among a hundred physicians who attended the conference (in person and virtually). We cover a broad range of performance metrics and shed light on leading indicators of success. Trended data and fully custom reporting (tied to strategic imperatives) help companies who have a presence at ASCO understand how well they did vs. the competition. 

Is your company already signed up for The Ipsos 2025 ASCO report? It’s not to late -- reach out for more information here!

In addition, the following Ipsos abstracts have been accepted as online publications this year:

1. Biomarker testing and patient demographic disparities among breast cancer patients across treatment settings.
2. Variations in PSMA PET utilization, PSA testing, and urologist involvement in advanced castrate resistant prostate cancer: Comparing academic and community practices in the US.
3. An observational study on the usage of GLP-1 in breast cancer patients in the US